NCT03833388View on ClinicalTrials.gov

Study of TOP1630 for Dry Eye Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

February 13, 2019

Primary Completion Date

May 14, 2019

Study Completion Date

May 14, 2019

Conditions
Dry Eye Syndrome
Interventions
DRUG

TOP1630 0.1% Ophthalmic Solution TID OU

Bilateral ocular drug administration

DRUG

Placebo to TOP1630 0.1% Ophthalmic Solution TID OU

Bilateral ocular drug administration

Trial Locations (4)

38119

Total Eye Care, Memphis

04240

Central Maine Eye Care, Lewiston

01810

Andover Eye Associates, Andover

02767

Suite 305, 775 Paramount Drive, Raynham

All Listed Sponsors
lead

Topivert Pharma Ltd

INDUSTRY

NCT03833388 - Study of TOP1630 for Dry Eye Syndrome | Biotech Hunter | Biotech Hunter